NANOBIOTIX Voting Rights and Shares Capital of the Company
Tweet
Share
E-mailIn accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: BISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com
| Date | Number of SharesOutstanding | Total number of voting rights | |
| Total voting rights,theoretical(1) | Total voting rights,exercisable(2) | ||
| October 31, 2022 | 34,875,872 | 36,286,313 | 36,273,212 |
(1) The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
(2) The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | |
| Nanobiotix CommunicationsBrandon OwensVP, Communications+1 (617) 852-4835[email protected] | Nanobiotix Investor RelationsKate McNeilSVP, Investor Relations+1 (609) 678-7388[email protected] |
| Media Relations | |
| France –Ulysse CommunicationPierre-Louis Germain+ 33 (0) 6 64 79 97 51[email protected] | LifeSci AdvisorsLigia Vela-Reid+44 (0) 7413825310[email protected] |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fort Technology Grants Restricted Share Units
- Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Tourism Minister of Bahrain Receives Senior UFI Delegation Ahead of 93rd UFI Global Congress
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
